1,344 Shares in Eli Lilly and Company (NYSE:LLY) Bought by New Wave Wealth Advisors LLC

New Wave Wealth Advisors LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,344 shares of the company’s stock, valued at approximately $1,217,000.

Several other hedge funds have also recently bought and sold shares of the company. J. W. Coons Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 4.0% in the fourth quarter. J. W. Coons Advisors LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after acquiring an additional 90 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of Eli Lilly and Company by 27.9% during the fourth quarter. Jones Financial Companies Lllp now owns 9,024 shares of the company’s stock worth $5,260,000 after buying an additional 1,967 shares during the last quarter. CWA Asset Management Group LLC increased its holdings in shares of Eli Lilly and Company by 32.7% during the fourth quarter. CWA Asset Management Group LLC now owns 3,272 shares of the company’s stock worth $1,907,000 after buying an additional 807 shares in the last quarter. Belpointe Asset Management LLC lifted its stake in shares of Eli Lilly and Company by 3.5% in the 4th quarter. Belpointe Asset Management LLC now owns 5,175 shares of the company’s stock valued at $3,017,000 after acquiring an additional 177 shares during the last quarter. Finally, ROI Financial Advisors LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at $9,181,000. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on LLY shares. Wells Fargo & Company upped their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Bank of America lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Truist Financial restated a “buy” rating and issued a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Barclays raised their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Finally, JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Stock Up 0.9 %

Eli Lilly and Company stock opened at $885.56 on Tuesday. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The firm’s 50-day simple moving average is $896.50 and its 200 day simple moving average is $844.99. The stock has a market cap of $841.64 billion, a PE ratio of 130.42, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Research analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 52,369 shares of the firm’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $915.18, for a total transaction of $47,927,061.42. Following the completion of the sale, the insider now directly owns 97,247,403 shares of the company’s stock, valued at approximately $88,998,878,277.54. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last three months, insiders have sold 364,810 shares of company stock worth $339,366,198. 0.13% of the stock is owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.